

Edgar Filing: SYNAPTIC PHARMACEUTICAL CORP - Form SC 13D/A

SYNAPTIC PHARMACEUTICAL CORP  
Form SC 13D/A  
March 07, 2003

SCHEDULE 13D/A  
(Amendment No. 3)

Under the Securities Exchange Act of 1934\*

SYNAPTIC PHARMACEUTICAL CORPORATION

-----  
(Name of Issuer)

Common Stock, \$0.01 Par Value

-----  
(Title of Class of Securities)

87156R109

-----  
(CUSIP Number)

Scott A. Arenare, Esq.  
Managing Director and General Counsel  
Warburg Pincus LLC  
466 Lexington Avenue  
New York, New York 10017  
(212) 878-0600

-----  
(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

Copies to:

Peter H. Jakes, Esq.  
Willkie Farr & Gallagher  
787 Seventh Avenue  
New York, NY 10019-6099  
(212) 728-8000

March 6, 2003

-----  
(Date of Event which Requires  
Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: [ ]

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of



Edgar Filing: SYNAPTIC PHARMACEUTICAL CORP - Form SC 13D/A

0%

14 TYPE OF REPORTING PERSON (See Instructions)

PN

Page 1 of 6

SCHEDULE 13D

CUSIP No. 87156R109

1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

Warburg Pincus & Co. I.R.S. #13-6358475

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)  
(a) [ ]  
(b) [x]

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

N/A

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS  
2 (d) or 2 (e) [ ]

6 CITIZENSHIP OR PLACE OF ORGANIZATION

New York

7 SOLE VOTING POWER

0

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON WITH

8 SHARED VOTING POWER

0

9 SOLE DISPOSITIVE POWER

0

10 SHARED DISPOSITIVE POWER

0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

Edgar Filing: SYNAPTIC PHARMACEUTICAL CORP - Form SC 13D/A

0

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
(See Instructions) [ ]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0%

14 TYPE OF REPORTING PERSON (See Instructions)

PN

Page 2 of 6

SCHEDULE 13D

-----  
CUSIP No. 87156R109  
-----

1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

Warburg Pincus LLC

I.R.S. #13-3536050

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)  
(a) [ ]  
(b) [X]

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

N/A

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS  
2 (d) or 2 (e) [ ]

6 CITIZENSHIP OR PLACE OF ORGANIZATION

New York

7 SOLE VOTING POWER

0

NUMBER OF  
SHARES

8 SHARED VOTING POWER

BENEFICIALLY  
OWNED BY EACH  
REPORTING

0

PERSON WITH

9 SOLE DISPOSITIVE POWER

0

10 SHARED DISPOSITIVE POWER

Edgar Filing: SYNAPTIC PHARMACEUTICAL CORP - Form SC 13D/A

0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
(See Instructions) [ ]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0%

14 TYPE OF REPORTING PERSON (See Instructions)

00

Page 3 of 6

This Amendment No. 3 (the "Amendment") amends and supplements the Schedule 13D originally filed on August 13, 2001 as amended and supplemented on August 26, 2001 by Amendment No. 1 and on November 22, 2002 by Amendment No. 2 ("Amendment No. 2") and is being filed on behalf of Warburg Pincus Private Equity VIII, L.P., a Delaware limited partnership ("WP VIII"), Warburg Pincus LLC, a New York limited liability company ("WP LLC") and Warburg Pincus & Co., a New York general partnership ("WP," and together with WP VIII and WP LLC, the "Reporting Persons").

Unless the context otherwise requires, references herein to the "Common Stock" are to shares of common stock, par value \$0.01 per share of Synaptic Pharmaceutical Corporation, a Delaware corporation (the "Company"). Unless otherwise indicated herein, each capitalized term used but not defined herein shall have the meaning assigned to such term in Amendment No. 2.

Item 4. Purpose of Transaction.

The information in Item 4 is hereby amended and restated in its entirety as follows:

The Merger contemplated by the Merger Agreement was consummated on March 6, 2003. As a result of the Merger, Sub was merged into the Company and each share of Series B Preferred Stock was converted into the right to receive \$1,499.15 in cash and each share of Series C Preferred Stock was converted into the right to receive \$1,088.54 in cash. Accordingly, the Reporting Persons are no longer the beneficial owners of any shares of Common Stock.

Page 4 of 6

Item 5. Interest in Securities of the Issuer.

(e) Each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the Common Stock on March 6, 2003.

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: March 6, 2003

WARBURG PINCUS PRIVATE EQUITY VIII,  
L.P.

By: Warburg Pincus & Co.,  
General Partner

By: /s/ Scott A. Arenare  
-----

Name: Scott A. Arenare  
Title: Partner

Dated: March 6, 2003

WARBURG PINCUS & CO.

By: /s/ Scott A. Arenare  
-----

Name: Scott A. Arenare  
Title: Partner

Dated: March 6, 2003

WARBURG PINCUS LLC

By: /s/ Scott A. Arenare  
-----

Name: Scott A. Arenare  
Title: Managing Director